NASDAQ:EXEL Exelixis Q3 2026 Earnings Date & Estimates $62.39 +0.16 (+0.26%) As of 11:51 AM Eastern This is a fair market value price provided by Massive. Learn more. Exelixis is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, after market closes. The conference call is scheduled for 5:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateOctober 29, 2026TimeAfter Market ClosesConference Call5:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Exelixis in Q3 2026Exelixis is expected to post earnings of $0.8790 per share on revenue of $646.95 million. In the same quarter a year earlier Exelixis reported $0.78 per share on revenue of $597.76 million. Exelixis last reported on August 5, 2026, posting $0.91 per share and beating the $0.8530 consensus estimate. Exelixis has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.8790Expected Revenue$646.95 millionPrior-Year EPS$0.78Prior-Year Revenue$597.76 millionExpected EPS Growth+12.7%Expected Revenue Growth+8.2%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.91 (Beat by +$0.0570)Last Quarter Revenue$628.69 millionEPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Exelixis Q3 2026 Earnings FAQ When does Exelixis report Q3 2026 earnings? Exelixis (NASDAQ:EXEL) is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Exelixis' Q3 2026 earnings call? Exelixis' Q3 2026 earnings conference call is scheduled for Thursday, October 29, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Exelixis? Analysts expect Exelixis to post earnings of $0.8790 per share for Q3 2026. How much revenue is Exelixis expected to report? The consensus revenue estimate for Exelixis is $646.95 million for Q3 2026. Exelixis Earnings HeadlinesExelixis (NASDAQ:EXEL) vs. Zymeworks (NASDAQ:ZYME) Financial Review4 hours ago | americanbankingnews.comKuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmOctober 12, 2026 | prnewswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 19 at 1:00 AM | Stansberry Research (Ad)Exelixis Inc stock hits all-time high at 61.21 USDOctober 12, 2026 | in.investing.comZacks Research Issues Negative Outlook for Exelixis EarningsOctober 12, 2026 | americanbankingnews.comZacks Research Has Positive View of Exelixis FY2028 EarningsOctober 11, 2026 | americanbankingnews.comSee More Exelixis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Exelixis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exelixis and other key companies, straight to your email. Email Address About ExelixisExelixis (NASDAQ:EXEL) is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression. Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Cabozantinib is also marketed as COMETRIQ for progressive, metastatic medullary thyroid cancer. The company continues to develop additional oncology candidates, including zanzalintinib, formerly known as XL092, and other pipeline programs involving targeted therapies and immuno-oncology combinations. Founded in 1994, Exelixis is headquartered in Alameda, California. Its medicines and development programs reach markets outside the United States through commercial operations and collaborations with international pharmaceutical companies. Michael M. Morrissey has served as the company’s president and chief executive officer since 2010.View Exelixis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Rate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are DivergingMarketBeat Week in Review – 10/12 - 10/16Could a Trucking Squeeze Become J.B. Hunt’s Biggest Edge?Meta Claims Frontier-Class AI Status With New Muse Wonder ModelsMicrosoft's New AI Chip Could Change the Economics of AIThese 3 Green Stocks Have a Growth Story That Goes Far Beyond WashingtonWomen Drive the Job Market—These 3 Stocks Are Following Them Upcoming Earnings America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026)Northrop Grumman (10/20/2026)RTX (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
